Eli Lilly and Company announced that the FDA has approved an additional indication for Jaypirca (pirtobrutinib, 100 mg & 50 mg tablets), a non-covalent Bruton tyrosine kinase (BTK) inhibitor,… read more.
Medtronic plc announced primary endpoint results from the SPYRAL AFFIRM post-approval study of the Symplicity Spyral renal denervation (RDN) system. The study showed statistically significant and clinically meaningful… read more.
People with type 2 diabetes were much more likely to achieve remission after weight-loss surgery than after intensive medical and lifestyle management, according to a long-term study. Researchers… read more.
Johnson & Johnson announced new three-year data from the Phase 3 GALAXI 2 and 3 studies showing durable efficacy and a consistent safety profile for TREMFYA (guselkumab) in… read more.
INOVIO announced that the FDA has granted accelerated approval for VOCERYQ (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd), previously referred to as INO-3107, to reduce the frequency of surgery in adults with RRP…. read more.
Pfizer Inc. announced that the FDA has expanded approval of Talzenna (talazoparib) in combination with Xtandi (enzalutamide) to the treatment of men with metastatic androgen pathway modulation-naïve or… read more.
Investigators have developed and validated a clinical decision support tool to improve the diagnosis and treatment of chronic kidney disease (CKD) at the point of care. The research… read more.
An updated Cochrane review has found that ergonomic interventions show no meaningful benefit for pain, function, recovery or sick leave in workers with work-related complaints of the arm,… read more.
Egetis Therapeutics AB announced that the FDA has approved Emcitate (tiratricol), a thyroid hormone receptor agonist, for the treatment of peripheral thyrotoxicosis in adults and pediatric patients with… read more.
Olezarsen can be used as an option to treat genetically confirmed familial chylomicronaemia syndrome in adults, only if response to diet and conventional triglyceride-lowering treatments (such as statins… read more.
Shanghai Junshi Biosciences Co., Ltd. announced that the National Medical Products Administration of China has converted from conditional approval to regular approval the toripalimab injection (trade name: TUOYI,… read more.
Mayo Clinic researchers have found that an artificial intelligence (AI) tool may provide dermatologists with additional information to help assess whether skin lesions are cancerous and inform their… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
